Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Work In Process: 2015-2025

Historic Work In Process for Amphastar Pharmaceuticals (AMPH) over the last 9 years, with Sep 2025 value amounting to $42.5 million.

  • Amphastar Pharmaceuticals' Work In Process rose 17.89% to $42.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.5 million, marking a year-over-year increase of 17.89%. This contributed to the annual value of $32.8 million for FY2024, which is 6.44% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Work In Process stood at $42.5 million, which was down 2.58% from $43.6 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Work In Process registered a high of $43.8 million during Q1 2025, and its lowest value of $28.3 million during Q3 2023.
  • In the last 3 years, Amphastar Pharmaceuticals' Work In Process had a median value of $33.3 million in 2024 and averaged $35.7 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Work In Process dropped by 26.63% in 2023 and then skyrocketed by 31.34% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Work In Process (Quarterly) stood at $33.3 million in 2021, then climbed by 11.39% to $37.1 million in 2022, then dropped by 16.90% to $30.8 million in 2023, then grew by 6.44% to $32.8 million in 2024, then increased by 17.89% to $42.5 million in 2025.
  • Its last three reported values are $42.5 million in Q3 2025, $43.6 million for Q2 2025, and $43.8 million during Q1 2025.